Clearside Biomedical shareholders approve doubling authorized common stock to 400M shares

Clearside Biomedical, Inc.

Shareholders approved amendment to increase authorized common shares from 200M to 400M; 38.8M for, 10.3M against, 0.6M abstain.
All three director nominees (Lasezkay, Shaffer, Gibney) were elected with >25M votes for.
Advisory vote on executive compensation approved: 18.9M for, 3.4M against, 6.8M abstain.
Ratification of Ernst & Young as auditor for FY2025 approved: 48.5M for, 1.2M against.

item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.